Stockreport

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Neumora Therapeutics, Inc.  (NMRA) 
PDF On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations pl [Read more]